Table 6.

Pre-existing concomitant somatic diseases* at baseline (in >5% of the patients, Prev-AP, FAS, N = 642)

		Prev-Olz	Prev-Risp	Prev-Quet	Prev-Atyp	Prev-Typ	Prev-Comb	Prev-None	FAS, total
		N = 62	N = 67	N = 49	N = 103	N = 90	N = 109	N = 162	N = 642
Any	n	23	20	15	36	36	45	46	221
	%	37.1	29.9	30.6	35.0	40.0	41.7	28.4	34.5
Hypertension	n	17	12	5	18	18	19	18	107
	%	27.4	17.9	10.2	17.5	20.0	17.6	11.1	16.7
Lipid disorders	n	4	7	4	4	7	12	5	43
	%	6.5	10.5	8.2	3.9	7.8	11.1	3.1	6.7
Diabetes	n	3	2	3	3	8	15	2	36
	%	4.8	3.0	6.1	2.9	8.9	13.9	1.2	5.6
Musculoskeletal disorders	n	1	4	2	4	6	9	8	34
	%	1.6	6.0	4.1	3.9	6.7	8.3	4.9	5.3

Abbreviations: FAS = full analysis set; Prev-AP = previous antipsychotic treatment

*pre-specified in data capturing form: diabetes, lipid metabolism disorder, other endocrine or metabolic disorders, liver disease, hypertension, heart and lung disease, gastrointestinal disease, urinary retention, hematological disease, thrombophilia or other coagulopathy, musculoskeletal disorders, neurological disorders, convulsions, kidney disorders, rheumatic disorder, malignant neoplasm/cancer